Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
10 p, 595.1 KB Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma / Wick, Antje (Heidelberg University Medical Center. Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center) ; Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ; Suarez, Cristina (VHIO) ; Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Burkholder, Tiana (Eli Lilly and Company) ; Cleverly, Ann Louise (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Wang, Shuaicheng (BioStat Solutions, Inc, Frederick, MD USA) ; Lahn, Michael M. (Eli Lilly and Company) ; Guba, Susan C. (Eli Lilly and Company) ; Capper, David (Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany) ; Rodon Ahnert, Jordi (VHIO) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00910-9) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.